Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...
pharmaphorum1d
A history of Sanofi
Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...
FiercePharma13d
Private equity firms bid on Sanofi's $16B+ consumer health business: Bloomberg
As private equity firms reportedly place their bids, Sanofi may soon follow in the footsteps of GSK and Johnson & Johnson ...
FiercePharma26d
Sanofi completes build out of $554M pandemic-ready modular plant for vaccines, biologics
In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.
Bloomberg L.P.7d
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. The ...
MedCity News26d
Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug
Sanofi is following several of its big pharma industry peers into radiopharmaceuticals, striking a deal for a clinical-stage therapy now in discussion for a regulatory submission as a treatment ...
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...
Benzinga.com4d
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...
STAT27d
After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on ...
MedCity News9d
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...
Business Insider26d
Sanofi, RadioMedix, Orano Med Sign Deal For Next-Gen Radioligand Medicine For Rare Cancers
(RTTNews) - Sanofi (SNYNF), RadioMedix, and Orano Med have announced a licensing agreement for a next-generation radioligand medicine targeting rare cancers. The collaboration between the ...
AOL14d
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
It has also been in talks to bring Abu Dhabi Investment Authority and Singapore sovereign fund GIC Pte into the consortium, the report added. As announced in October 2023, Sanofi is reviewing ...